The competitive landscape of the GLP-1 weight-loss drug market has shifted notably, as Denmark’s Zealand Pharma suffered a major setback with its new obesity treatment, while industry leader Eli Lilly (LLY) notched two major wins to further cement its market dominance.
Zealand Pharma’s GLP-1 dual agonist Servodutide delivered disappointing results in its Phase III trial. While the drug managed to reduce liver fat and support weight loss among participants, its safety profile raised serious concerns. A total of 19% of trial participants dropped out due to gastrointestinal side effects including nausea, vomiting and diarrhea, and more than 40% reported vomiting episodes. Such adverse reaction rates are far above the standard seen with leading rival therapies, casting a shadow over Servodutide’s commercial prospects. The setback triggered a nearly 23% plunge in Zealand Pharma’s share price.
In stark contrast, Eli Lilly unveiled encouraging clinical data for its next-generation weight-loss candidate Retatrutide at the American Diabetes Association’s annual meeting in New Orleans. Full Phase III results showed the 4 mg low dose of the triple receptor agonist achieved around 19% weight reduction, matching the efficacy of the highest dose of its blockbuster drug Zepbound. The treatment also demonstrated strong tolerability, with just 4% of participants discontinuing treatment over adverse reactions. Lilly additionally released positive data for its oral weight-loss pill and experimental injectable eloralintide, widening its edge over peers with a richer product pipeline.
Beyond its thriving obesity drug franchise, Lilly is actively building new growth drivers. The company has completed three separate acquisitions worth over $3.8 billion in total to foray into infectious disease vaccines. It took over Curevo, LimmaTech Biologics and Vaccine Company in coordinated deals. Curevo’s candidate for shingles generates an immune response on par with GSK’s top-selling vaccine while cutting side effects by more than half. LimmaTech focuses on vaccines against drug-resistant bacterial pathogens, and Vaccine Company develops shots targeting the Epstein-Barr virus, a pipeline with multi-billion-dollar market potential.
Fueled by its popular weight-loss medications, Lilly’s annual revenue jumped from $34.1 billion in 2023 to $65.2 billion in 2025. Looking past the limits of the obesity drug market, the firm has also expanded into gene editing, cardiovascular therapies, oncology and other areas to build a diversified business portfolio.
Market movements clearly reflect the diverging fortunes across the sector. Eli Lilly’s pre-market shares surged 4% on the news, bringing its year-to-date gain to 5.2% and pushing its market value above $1 trillion. Its key peer Novo Nordisk has struggled meanwhile, with its stock down roughly 15% so far this year amid lackluster pipeline progress.
Analysts believe Retatrutide’s solid performance will help Lilly maintain its leadership in the lucrative GLP-1 segment. Its bold push into vaccines also marks a strategic transformation from a pure-play weight-loss drug giant to a diversified pharmaceutical powerhouse. With robust core business and promising new growth lines, Lilly is well-positioned to hold onto its trillion-dollar valuation and reshape the global healthcare industry landscape.
